Search

Dexamethasone acetate

one-fifth and one-third in patients on oxygen therapy and mechanical ventilation, respectively. … [T797,L10695,L14348] Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as [hydrocortisone] and [prednisolone].

Telapristone acetate

Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

AEG35156

AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. … This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis.

Lesopitron

Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

Veltuzumab

Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

N-chlorotaurine

N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

Liatermin

Vapitadine

Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis … An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.

Protriptyline

The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

Ganstigmine

Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.